Savara (SVRA) Stock: Buy, Sell, or Hold?
SVRA - Savara Inc.
$4.81
-0.24 (-4.66%)
▼
5d:
-3.8%
30d:
-11.9%
90d:
-22.42%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 25, 2026 at $5.00 · last confirmed Oct 2, 2026
Strength: 8.0/10
Get Alerted When SVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SVRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SVRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SVRA is currently trading at $4.81, which is considered oversold relative to its 30-day fair value range of $5.10 to $5.49.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $4.76. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: SVRA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.94 (+127.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $4.76. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: SVRA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.94 (+127.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.10 -
$5.49
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 127.4% below Wall St target ($10.94)
Trading Range Analysis
30-Day Trading Range
$5.10 -
$5.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.77
Resistance Level
$5.53
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.42
Wall Street Target
$10.94
(+127.4%)
Share & Embed Analysis
Last updated: October 03, 2026 9:57 PM ET
Data refreshes hourly during market hours. Next update: 10:57 PM
Data refreshes hourly during market hours. Next update: 10:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |